TransCode Therapeutics, Inc. (RNAZ) Revenue History
Annual and quarterly revenue from 2018 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
RNAZ Revenue Growth
RNAZ Revenue Analysis (2018–2024)
As of May 8, 2026, TransCode Therapeutics, Inc. (RNAZ) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, RNAZ's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including ARWR (+14.1% YoY), NTLA (+16.9% YoY), and SRPT (-2.2% YoY). Compare RNAZ vs ARWR →
RNAZ Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| RNAZCurrent | $0 | - | - | - | |
 ARWR | $829M | +14.1% | +56.6% | 11.9% | |
 NTLA | $68M | +16.9% | +3.1% | -651.7% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 MRNA | $1.9B | -29.1% | +19.3% | -158.1% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% |
RNAZ Historical Revenue Data (2018–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $0 | - | $-534,857 | - | $-15,660,697 | - |
| 2023 | $0 | - | $-516,746 | - | $-19,418,516 | - |
| 2022 | $0 | - | $-98,606 | - | $-18,665,814 | - |
| 2021 | $0 | - | $-42,470 | - | $-6,151,135 | - |
| 2020 | $0 | - | $0 | - | $-726,604 | - |
| 2019 | $0 | - | $0 | - | $-456,865 | - |
| 2018 | $0 | - | $0 | - | $-383,996 | - |
See RNAZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RNAZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RNAZ vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRNAZ — Frequently Asked Questions
Quick answers to the most common questions about buying RNAZ stock.
Is RNAZ's revenue growth accelerating or slowing?
RNAZ TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is RNAZ's long-term revenue growth rate?
TransCode Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is RNAZ's revenue distributed by segment?
RNAZ reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2024 are available for download. Segment mix reveals concentration and diversification trends.